SCHEMBL14330491

SCHEMBL14330491

c1ccc2c(c1)cc(-n1c3cccnc3c3c4ccc5cccc6ccc(cc31)c4c65)c1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 5/20 0.44
▸ ERBB2 P04626 1/20 0.44
▸ FYN P06241 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ ACHE P22303 1/20 0.44
▸ AHR P35869 1/20 0.44
▸ CYP2C19 P33261 2/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ TDP1 Q9NUW8 2/20 0.35
▸ CYP3A4 P08684 4/20 0.34
▸ HPGD P15428 3/20 0.34
▸ GAA P10253 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ THRB P10828 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ CCR1 P32246 4/20 0.33
▸ CCR8 P51685 4/20 0.33
▸ CCR5 P51681 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ LMNA P02545 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14329607 0.96 CYP1A2 (0.39) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14329591 0.87 KDM4E (0.39) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14329582 0.85 CYP3A4 (0.40) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14330495 0.83 CYP1A2 (0.40) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14330490 0.80 CYP1A2 (0.35) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14329610 0.79 ALDH1A1 (0.33) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14330573 0.79 CYP1A2 (0.44) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14330538 0.79 MAOA (0.44) CYP1A2ERBB2FYNMAOAACHE
SCHEMBL14329601 0.79 TOP1 (0.36) TDP1CYP3A4CCR1CCR8CCR5
SCHEMBL13556840 0.79 ALDH1A1 (0.38) CYP1A2CYP2C19CYP2C9TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623521-B2 Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound SAMSUNG DISPLAY CO., LTD. (KR) 2014-01-07 — — US disclosed
US-8623521-B2 Heterocyclic compound and organic light-emitting diode and flat display device including the heterocyclic compound SAMSUNG DISPLAY CO., LTD. (KR) 2014-01-07 — — US disclosed
US-20120326134-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2012-12-27 — — US disclosed
US-20120326134-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND SAMSUNG DISPLAY CO., LTD. (KR) 2012-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120326134-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE AND FLAT DISPLAY DEVICE INCLUDING THE HETEROCYCLIC COMPOUND DDT, DRD1, HTR3D CYP1A2 60/4885ERBB2 1188/4885FYN 1663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback